Goji Berries and Energy Expenditure
31 januari 2017 bijgewerkt door: Maastricht University Medical Center
The Effect of a Single Dose of Lycium Barbarum on Postprandial Energy Expenditure in Healthy Overweight Men
Effects of foods or food substances on energy expenditure are of particular interest, because of the increasing prevalence of obesity and its consequent metabolic diseases like type II diabetes and fatty liver disease, all risk factors for the development of cardiovascular diseases (CVDs).
Recently, the Goji berry (Lycium Barbarum, wolfberry) was introduced into the Western diet.
L. Barbarum originates from Asia, where it is used to improve the health of several organs.
Although L. Barbarum is promoted as a super food with many beneficial effects, consistent scientific evidence for these effects is lacking.
In one study, it was found that short-term intake of L. Barbarum polysaccharides - equal to 150 g of fresh berries - increased postprandial oxygen consumption.
This indicates that L. Barbarum might exert beneficial effects on energy expenditure.
Furthermore, long-term intervention trials have shown beneficial effects of L. Barbarum on lipid and glucose metabolism in mice and type II diabetic patients and on inflammatory status in healthy elderly.
Altogether, L. Barbarum has the potential to be used as a functional food to increase metabolic health, but detailed information on the postprandial effects of L. Barbarum is missing.
We therefore propose this double-blinded, randomized, placebo controlled intervention trial to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure substrate oxidation, metabolic flexibility, lipid and glucose metabolism and inflammatory markers.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Objectives:
The primary objective of this study is to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure. Secondary objectives are to investigate the effect of a single dose of L. Barbarum on postprandial lipid and carbohydrate oxidation and metabolic flexibility, on postprandial lipid and glucose metabolism and on inflammatory markers.
Study design:
This is a double blind, randomized, placebo-controlled intervention trial with two test days separated by a washout period of at least 1 week.
Study population:
The study population will consist of 20 apparently healthy overweight (BMI between 25 and 30 kg/m2) men aged 18-65 years.
Intervention:
All subjects will receive a mixed meal including 25 grams of dried L. Barbarum as the intervention product and a matched mixed meal without L. Barbarum as the placebo product. The meals will be matched for energy content and macronutrient composition.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
18
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Limburg
-
Maastricht, Limburg, Nederland, 6229 ER
- Maastricht University Medical Center
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 65 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Mannelijk
Beschrijving
Inclusion Criteria:
- Male gender
- BMI between 25 and 30 kg/m2
- Non-smoking
- Normal fasting triacylglycerol levels (<2.2 mmol/L)
- No hyperglycaemia or hypercholesterolemia (fasting glucose < 7.0 mmol/L and total cholesterol < 8.0 mmol/L)
- Willing to comply to the study protocol during the study
- Agreeing to be informed about medically relevant personal test-results
Exclusion Criteria:
- Use of anticoagulant medication
- Unstable body weight (weight gain or loss >3 kg in the past 3 months)
- Indications of treatment according to the Standard for Cardiovascular Risk Management from the Dutch General Practitioners community
- Any medical condition that might interfere with study measurements, judged by the principal investigator, including cardiovascular disease or events (e.g. acute myocardial infarction or cerebra-vascular accident), diabetes or hypercholesterolemia
- Use of any kind of medication or medically prescribed diet, which can interfere with the study (judged by the principal investigator). The use of paracetamol is allowed
- Use of oral antibiotics (with the exception of topical antibiotics) in 40 days or less prior to the start of the study
- Use of food supplements or plant-sterol/stanol-enriched foods or supplements in the three weeks prior to the screening and/or during the study
- Not willing to abstain from L. Barbarum consumption thee weeks before the start and during the trial
- Severe medical conditions that might interfere with the study, such as epilepsy, asthma, chronic obstructive pulmonary disease and rheumatoid arthritis
- Consumption of > 14 alcohol consumptions a week
- Reported intense sporting activities > 10 hours a week
- Abuse of drugs
- Participation in any other biomedical trial one month prior to the screening visit
- Having donated > 150 ml blood within 1 month prior to the screening visit, planning to donate blood during the study or within one month after finishing the study
- Impossible or difficult to puncture as evidenced during the screening visit
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Lycium Barbarum mixed meal
Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
|
This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
|
|
Actieve vergelijker: Control mixed meal
Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
|
This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline energy expenditure
Tijdsspanne: Measured as the incremental area under the curve (iAUC) from 0 minutes to 140 minutes after meal intake
|
Energy expenditure will be measured using indirect calorimetry (ventilated hood system).
This system measures oxygen consumption (VO2) and carbon dioxide production (VCO2) to calculate the energy expenditure (kJ/min)
|
Measured as the incremental area under the curve (iAUC) from 0 minutes to 140 minutes after meal intake
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline energy expenditure
Tijdsspanne: Measured as the incremental area under the curve (iAUC) from 160 minutes to 200 minutes and from 220 minutes to 260 minutes after meal intake
|
Energy expenditure will be measured using indirect calorimetry (ventilated hood system).
This system measures VO2 and VCO2 to calculate the energy expenditure (kJ/min).
|
Measured as the incremental area under the curve (iAUC) from 160 minutes to 200 minutes and from 220 minutes to 260 minutes after meal intake
|
|
Postprandial lipid and glucose oxidation
Tijdsspanne: At baseline (T0, fasting) and between 0 minutes and 140 minutes, between 160 minutes and 200 minutes and between 220 minutes and 260 minutes after meal consumption
|
Lipid and glucose oxidation will be calculated from indirect calorimetry data (VO2 and VCO2).
|
At baseline (T0, fasting) and between 0 minutes and 140 minutes, between 160 minutes and 200 minutes and between 220 minutes and 260 minutes after meal consumption
|
|
Metabolic flexibility
Tijdsspanne: At 60, 120, 180 and 240 minutes after meal intake
|
Metabolic flexibility will be derived from indirect calorimetry as the difference in respiratory quotient (RQ) between fasting and postprandial conditions.
|
At 60, 120, 180 and 240 minutes after meal intake
|
|
Markers for lipid metabolism
Tijdsspanne: At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
Several markers for lipid metabolism will be measured in blood samples.
|
At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
|
Markers for glucose metabolism
Tijdsspanne: At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
Several markers for glucose metabolism will be measured in blood samples.
|
At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
|
Inflammatory status
Tijdsspanne: At baseline (T0) and at 60, 120, 180 and 240 minutes after meal consumption
|
Several markers for inflammatory status will be measured in blood samples and in vitro conditions
|
At baseline (T0) and at 60, 120, 180 and 240 minutes after meal consumption
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 april 2016
Primaire voltooiing (Werkelijk)
1 december 2016
Studie voltooiing (Werkelijk)
1 december 2016
Studieregistratiedata
Eerst ingediend
18 april 2016
Eerst ingediend dat voldeed aan de QC-criteria
18 mei 2016
Eerst geplaatst (Schatting)
23 mei 2016
Updates van studierecords
Laatste update geplaatst (Schatting)
1 februari 2017
Laatste update ingediend die voldeed aan QC-criteria
31 januari 2017
Laatst geverifieerd
1 april 2016
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- METC 15-3-060
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .